Seattle biotech company Omeros Corp. is seeking accelerated approval from the Federal Drug Administration for its drug that aims to fight a life-threatening disorder that can develop after receiving a stem cell transplant. Last month, Seattle Genetics received accelerated approval for one of its new drugs from the FDA, several months in advance of when approval was expected. Omeros seeks the same designation this year.
On Tuesday, Omeros received a positive adjustment to its Relative Strength (RS) Rating, from 67 to 75. Over 100 years of market history shows that the market's biggest winners tend to have an RS Rating north of 80 as they launch their largest runs. See if Omeros can continue to show renewed price strength and clear that threshold.
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2019, which include:
Q1 2020 Omeros Corp Earnings Call
Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Omeros Corporation (Nasdaq: OMER) today announced that the results of its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy will be presented at the 25th Annual Congress of the European Hematology Association (EHA) to be held June 11-14, 2020. This year the congress will be held virtually.
Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its first quarter financial results for the period ended March 31, 2020, on Monday, May 11, 2020, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
Q4 2019 Omeros Corp Earnings Call
Q3 2019 Omeros Corp Earnings Call
All forward-looking statements involve risks and uncertainties that could cause the company's actual results to differ materially. Please refer to the special note regarding forward-looking statements and the risk factors section in the company's quarterly report on Form 10-Q, which was filed today with the SEC, and the risk factors section of the company's 2019 annual report on Form 10-K for a discussion of these risks and uncertainties. Greg Demopulos, chairman and CEO of Omeros, will take you through a corporate update, and then Mike Jacobsen, our chief accounting officer, will provide an overview of our first-quarter financial results.
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of ...
Omeros Corporation (Nasdaq: OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2020, which include:
Companies in the news are: SCON, OMER, QGEN, TLRY
Omeros Corporation (Nasdaq: OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), markedly exceeding the FDA-agreed threshold for the primary efficacy endpoint. While an overview of preliminary data submitted to FDA was made public on December 4, 2019 in a press release from the company, all patients have now completed treatment and trial enrollment has been closed. Narsoplimab is Omeros’ human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2).
Shares of thinly-traded small-cap biopharma Omeros Corporation (NASDAQ: OMER) are advancing Wednesday following a positive readout from a pivotal Phase 3 study of its investigational asset narsoplimab. Omeros said the pivotal study that evaluated narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy, or HCST-TMA, met the composite primary endpoint and the secondary endpoints. Narsoplimab is Omeros' lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2.
Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Gregory Demopulos became the CEO of Omeros Corporation (NASDAQ:OMER) in 1994. This report will, first, examine the CEO...
Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (OMER). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Omeros and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.